Regenxbio (RGNX) Receivables (2014 - 2026)
Regenxbio (RGNX) posted quarterly Receivables of $39.6 million for Q4 2025, up 22.76% year-over-year from $32.3 million in Q4 2024, and down 22.18% quarter-over-quarter from $50.9 million in Q3 2025.
Regenxbio (RGNX) Receivables (2014 - 2026) Analysis & Trends
Regenxbio's Receivables history runs 12 years deep, the most recent figure standing at $39.6 million for Q4 2025.
- In Q4 2025, Receivables rose 22.76% year-over-year to $39.6 million; the TTM figure through Dec 2025 stood at $39.6 million (up 22.76% YoY), while the FY2025 annual figure was $39.6 million, down 3.56% from the prior year.
- Receivables for Q4 2025 stood at $39.6 million, down from $50.9 million in the prior quarter.
- The five-year high for Receivables was $77.7 million in Q3 2021, with the low at $19.4 million in Q1 2025.
- The 5-year median for Receivables is $32.0 million (2024), against an average of $40.2 million.
- The sharpest annual moves came in 2023 and 2025: Receivables slumped 66.41% in 2023, then jumped 109.64% in 2025.
- Regenxbio's Receivables stood at $35.8 million in 2021, then grew by 0.29% to $35.9 million in 2022, then slipped by 15.02% to $30.5 million in 2023, then increased by 5.77% to $32.3 million in 2024, then advanced by 22.76% to $39.6 million in 2025.
- Business Quant data shows RGNX's Receivables at $39.6 million in Q4 2025, $50.9 million in Q3 2025, and $21.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 117.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 117.73 Mn |
| Dec 31, 2025 | 39.59 Mn |
| Sep 30, 2025 | 50.87 Mn |
| Jun 30, 2025 | 21.81 Mn |
| Mar 31, 2025 | 19.44 Mn |
| Dec 31, 2024 | 32.25 Mn |
| Sep 30, 2024 | 24.27 Mn |
| Jun 30, 2024 | 23.47 Mn |
| Mar 31, 2024 | 31.66 Mn |
| Dec 31, 2023 | 30.49 Mn |
| Sep 30, 2023 | 31.12 Mn |
| Jun 30, 2023 | 24.52 Mn |
| Mar 31, 2023 | 22.16 Mn |
| Dec 31, 2022 | 35.88 Mn |
| Sep 30, 2022 | 66.75 Mn |
| Jun 30, 2022 | 73.01 Mn |
| Mar 31, 2022 | 30.23 Mn |
| Dec 31, 2021 | 35.78 Mn |
| Sep 30, 2021 | 77.73 Mn |
| Jun 30, 2021 | 69.68 Mn |